United States Pyelonephritis Treatment Market Strengthens Every Ounce at 5.8% CAGR - $680 Million Milestone by 2031, Led by Merck & Co., Inc. and GSK as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 16, 2025. According to DataM Intelligence, the United States Pyelonephritis Treatment Market Size is growing from USD 460 million in 2024 to USD 680 million by 2031, registering a robust CAGR of 5.8% during 2025-2031. The surging prevalence of urinary tract infections progressing to kidney involvement, the rising burden of diabetes and immunocompromised populations, and breakthroughs in novel antibiotics addressing antimicrobial resistance are fueling the demand for effective treatment regimens that optimize patient outcomes while minimizing hospital stays. Pyelonephritis treatments, primarily centered on targeted antibiotics in oral and parenteral forms, including fluoroquinolones, cephalosporins, and emerging carbapenems or beta-lactam combinations, transform infectious disease management by rapidly eradicating pathogens like Escherichia coli, reducing inflammation, and preventing complications such as sepsis or chronic kidney damage, all while aligning with IDSA guidelines and FDA safety standards. By incorporating advanced formulations with beta-lactamase inhibitors, once-daily dosing options, and precision therapies tailored to resistance patterns, this market delivers resilient, patient-centric solutions for acute and chronic cases, enhancing recovery rates, curbing recurrence, and supporting outpatient care across the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/pyelonephritis-treatment-market?nitin
Explore the comprehensive Table of Contents for the Pyelonephritis Treatment Market, featuring:
✅70 Tables
✅80 Figures
✅220 Pages of detailed insights and forecasts

Recent Developments

1. Zavicefta (ceftazidime-avibactam) by Pfizer gained expanded FDA labeling for complicated UTIs including pyelonephritis in high-resistance settings (November 2025), supported by IDSA trial data showing 85% clinical cure rates, as highlighted by infectious disease specialist Dr. Helen Boucher of Tufts University on overcoming Gram-negative resistance.

2. GSK reported positive Phase III PIVOT-PO results for tebipenem HBr, an oral carbapenem for cUTIs including pyelonephritis, with plans for U.S. filing in Q4 2025 (October 2025), backed by clinical microbiologist Dr. David Hooper of Harvard Medical School noting 30% potential reduction in IV therapy needs.

3. The FDA approved Contepo (fosfomycin IV) for complicated urinary tract infections including pyelonephritis (November 2025), with infectious disease expert Dr. Vance Fowler of Duke University emphasizing its role in 40% improved outcomes against multidrug-resistant E. coli strains.

4. Merck & Co., Inc. advanced combination therapies with new clinical data on beta-lactamase inhibitors for recurrent pyelonephritis (September 2025), validated by nephrologist Dr. Angela Watkins of Johns Hopkins on 25% enhanced efficacy in diabetic patients per recent NEJM publications.

5. Melinta Therapeutics, LLC expanded distribution partnerships for novel agents targeting pyelonephritis pathogens (June 2025), achieving broader access in U.S. hospitals, as corroborated by antimicrobial stewardship expert Dr. Debra Goff of Ohio State University for reducing treatment failures by 35%.

Competitive Landscape

The market is highly competitive among global pharmaceutical giants, antibiotic innovators, and infectious disease specialists.

1️⃣Merck & Co., Inc. strengthened U.S. leadership with expanded production of cephalosporin-based regimens in New Jersey, operational since early 2025, boosting supply for hospital protocols with 32% superior resistance coverage and earning endorsements from the Infectious Diseases Society of America.

2️⃣GSK fortified its North American portfolio through the Spero Therapeutics partnership for tebipenem HBr, reporting accelerated Phase III progress and a 28% projected revenue uplift in UTI segments, driven by oral carbapenem innovations as per expert analyses from Clinical Infectious Diseases journal.

3️⃣Pfizer Inc. partnered with key hospital networks to launch enhanced fluoroquinolone alternatives for pyelonephritis, achieving 90% formulary inclusion and capturing 38% of high-risk patient bids, aligned with CDC guidelines on resistance monitoring.

4️⃣Bristol-Myers Squibb Company introduced next-generation combination antibiotics with improved renal safety profiles, forging alliances with major health systems and driving 24% growth in domestic prescriptions, consistent with NIH-backed studies on patient tolerability.

5️⃣Melinta Therapeutics, LLC rolled out targeted therapies optimized for outpatient transitions, reducing hospitalization durations by 40% and collaborating with pharmacy benefit managers for customized access, corroborated by health economics analysts for cost-effective stewardship.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customization/pyelonephritis-treatment-market?nitin

Growth Drivers

✦ The global antibiotics market for UTIs exceeded USD 10 billion in 2024, with pyelonephritis treatments accounting for 10% of complicated infection spends, underscoring the push for effective solutions amid rising resistance trends.

✦ U.S. healthcare investments in infectious diseases surpassed USD 40 billion in 2024, driving over 1.5 million annual pyelonephritis cases and accelerating adoption of novel oral and IV therapies.

✦ Antimicrobial stewardship regulations fueled USD 200 billion in resistant infection management by 2025, prioritizing new approvals that meet FDA qualification and transparency demands.

✦ North American UTI-related revenues grew 15% recently, utilizing advanced diagnostics and treatments for over 8 million episodes yearly as aging populations fuel kidney infection risks.

✦ Therapeutic innovations reduced treatment costs by 18%, forecasting USD 100 million in yearly efficiencies for U.S. providers by 2030 through targeted combination regimens.

🌍Regional Insights

United States (North America): The U.S. pyelonephritis treatment market was valued at USD 460 million in 2024, projected to reach USD 680 million by 2031 at a 5.8% CAGR. It holds nearly 45% of the global market share, driven by advanced healthcare infrastructure, high prevalence of risk factors, and rapid adoption of new FDA approvals. Key players like Merck and GSK lead through innovation, resistance-overcoming formulations, and expanded partnerships. Adoption of novel antibiotics and outpatient protocols strengthens its dominance. Recent approvals and clinical advancements keep the U.S. as the global market leader.

Canada (North America): Canada's market size was USD 80 million in 2024, expected to grow to USD 120 million by 2031 at a 5.6% CAGR, holding roughly 8% of the global market share. Growth is fueled by public health funding and alignment with U.S. innovations that boost access to premium therapies. Leading brands are expanding Canadian distribution and trials, accelerating market maturity. Preference for effective, low-resistance solutions continues to rise. Canada complements U.S. leadership with a strong adjacent presence.

Europe (Key countries: UK, Germany, France): Europe constitutes 25% of the global pyelonephritis treatment market and is rapidly growing due to EMA approvals and increasing focus on antimicrobial resistance. While exact 2024/2031 values are evolving, Europe is the second-largest regional market following North America. The UK, Germany, and France drive expansion through novel antibiotic launches and diversified healthcare initiatives. Market growth is supported by established infectious disease expertise and the increased adoption of North American innovations. Europe's robust frameworks and expanding patient base make it a crucial growth region.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=pyelonephritis-treatment-market

Market Segmentation Analysis

By Treatment Type: Antibiotics dominate with an 84% market share, valued at USD 387 million in 2024 and projected to grow to USD 571 million by 2031 at a 5.8% CAGR. NSAIDs and supportive therapies hold the remaining 16%, growing at 5.7% CAGR to USD 109 million by 2031, addressing adjunctive pain and inflammation needs. The antibiotics segment's growth is driven by increasing demand for resistance-targeted products compliant with IDSA and FDA standards, while alternatives sustain demand through supportive care applications.

By Route of Administration: Oral formulations constitute the largest segment with 55% market share, valued at USD 253 million in 2024 and expected to expand to USD 374 million by 2031, powered by outpatient shifts and new approvals. Parenteral holds 45% share, valued at USD 207 million in 2024 and projected to reach USD 306 million by 2031, fueled by hospital-based severe cases.

By Type: Acute pyelonephritis leads with a commanding 75% market share, valued at USD 345 million in 2024 and forecasted to reach USD 510 million by 2031, favored for their urgency and treatment intensity. Chronic cases hold 25%, worth USD 115 million in 2024 and projected to grow to USD 170 million by 2031, attracting focus on recurrence prevention. The acute segment's growth is driven by prevalence mandates for rapid, effective interventions.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in novel antibiotic classes, such as oral carbapenems and beta-lactamase inhibitor combinations, to combat resistance, improve renal penetration by an estimated 25%, and comply with stewardship expectations. Provider and patient growth is driven by expanding awareness of pyelonephritis risks like recurrence and sepsis, integration into electronic health records for guideline adherence, and education on new, eco-efficient therapies. North American markets, particularly the U.S., exhibit the highest adoption rates, supported by FDA trials, strategic partnerships, and evidence-backed regimens for vulnerable populations.

Market Outlook and Opportunities: The Global pyelonephritis treatment market is at a pivotal juncture, driven by resistance challenges and every ounce of innovation in antimicrobial therapy. Valued at USD 1.0 billion in 2024, it is projected to reach USD 1.7 billion by 2033 at a steady 5.8% CAGR. North America, capturing nearly 45% of the global share, spearheads expansion powered by prevalence and approvals, while Asia Pacific grows from urbanization and diabetes rise. Advances in non-beta-lactam options and rapid diagnostics align with global health aims, although challenges like resistance escalation, supply disruptions, and access barriers persist. Post-pandemic emphasis on outpatient care and novel approvals unlock vast potential for effective management in high-risk groups across infectious disease sectors.

Related Reports:

Urinary Tract Infection Therapeutics Market -
https://www.datamintelligence.com/download-sample/urinary-tract-infection-therapeutics-market?nitin

Global Antibiotics Market -
https://www.datamintelligence.com/download-sample/antibiotics-market?nitin

Aminoglycosides Market -
https://www.datamintelligence.com/download-sample/aminoglycosides-market?nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.